美德纳Moderna Inc. (MRNA) 2020年年度报告「NASDAQ」.pdf

1、2120192020 annual report387938_MRNA002_AR_2020_COVER_HR.indd 13/3/21 3:09 AMDeliver on the promise of mRNA science to create a new generation of transformative medicines for patients.2010 founding year1,300+team membersCambridge,MAheadquarters5therapeutic areas:Infectious DiseasesImmuno-OncologyRare

2、 DiseasesCardiovascular DiseasesAutoimmune Diseases46%women in our workforceOur missionAll figures as of December 31,2020,except for development programs,which is to date.13having entered the clinic24development programs32,000+participants enrolled in clinical trials$5.25Bcash,cash equivalents,and i

3、nvestments387938_MRNA002_AR_2020_COVER_HR.indd 23/3/21 3:09 AM3moderna 2020annual report|Table of contents4A letter from our CEO24 Pipeline26 COVID-19 response timeline28 Building our team,advancing ourculture30 Corporate citizenship32 Leadership33 Awards and recognition34 Financials4|moderna 2020an

4、nual reportA letter from our CEOJANUARY 4,2021 Cambridge,Mass.,USA“Moderna is now a commercial company.”Stphane Bancel Chief Executive Officer5moderna 2020annual report|By nearly all measures,2020 was a historic year in our lives.It was also a historic year forModerna.We started the year not knowing

5、 there was going to be a new virus,which would be declared a global pandemicthe first of its kind in 100years since the Spanish flu.We ended the year with an Emergency Use Authorization from the U.S.Food and Drug Administration(FDA)and an Interim Order from Health Canada for use of ourCOVID-19vaccin

6、e.Today,our team is working as hard as they can to manufacture with high quality as many doses of the vaccine as they can.We know that each additional dose we can make will be used to protect one more life.It took our team less than 12 months to go from the sequence made available online by the Chin